| Project/Area Number |
15K20173
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Otorhinolaryngology
|
|---|
| Research Institution | Center for Clinical and Biomedical Research, Sapporo Higashi Tokushukai Hospital (2016)
Asahikawa Medical College (2015) |
|---|
Principal Investigator |
Komabayashi Yuki 医療法人徳洲会札幌東徳洲会病院付属臨床研究センター, がん研究部, 研究員 (40548864)
|
|---|
| Project Period (FY) |
2015-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2015: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
|
|---|
| Keywords | EBウイルス / microRNA / 悪性リンパ腫 / miR-BART2-5p / 頭頸部外科 / マイクロRNA / 頭頸部外科学 / 悪性腫瘍 |
|---|
| Outline of Final Research Achievements |
Nasal natural killer /T-cell lymphoma is an Epstein-Barr virus (EBV)-associated malignancy and is characterized by a poor prognosis. Sera of patients with nasal natural killer /T-cell lymphoma were subjected to PCR-based EBV-miRNA profiling. This analysis revealed high miR-BART2-5p expression level in sera of patients. Level of miR-BART2-5p significantly decreased after treatment compared with those before treatment. Furthermore, a high circulating miR-BART2-5p level was associated with disease progression and poor prognosis in patients with nasal natural killer /T-cell lymphoma. Our findings suggest that circulating miR-BART2-5p may serve as a potential biomarker in patients with nasal natural killer /T-cell lymphoma.
|
